|
|
1900 9th Ave., Suite 200
Seattle, WA 98101 USA
phone:206-366-3700
fax:206-366-4700
|
|
| Symbol |
CRXA |
| Exchange |
|
| Founded |
1994 |
| Employees |
366 |
|
|
| www.corixa.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development and discovery of immunotherapeutic products |
|
| Management |
| CEO: Steven Gillis, Ph.D., CEO Vice Chairman: Michael Bigham CFO: Michelle Burris |
| |
|
|
|
|
|
|
|
| Keywords |
| oncology, Bexxar, immunotherapeutics, immune system, medarex, rituximab-refractory, antibody, vaccine, infectious disease, agonists, antagonists, adjuvants, chemotherapy, cancer, InfectiousDisease |
|
|
|
| Description |
|
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling vaccine design and the use of its separate, proprietary product components on a stand-alone basis. Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to or through late stage clinical trials. |
|
| Products / Services |
Corixa Corporation is a product development company with multiple product candidates in human clinical trials. The Company engages in the discovery and development of immunotherapeutic products, products that work by affecting the immune system, to address debilitating and life-threatening conditions. The Company's primary therapeutic approaches include antibody-based therapeutics, therapeutic vaccines for cancer and infectious disease, agonists and antagonists of innate immune responses and adjuvants designed to increase the effectiveness of its and its partner's vaccines. The Company has one product on the market in Canada and, together with its partners, is conducting late-stage clinical trials for several product candidates targeting a range of cancers, infectious diseases and autoimmune diseases.
|
|
| Technology / Differentiation |
| The FDA approved BEXXAR for the treatment of patients with CD20 positive, follicular, NHL, with and without transformation, whose disease refractory to Rituximab and has relapsed following chemotherapy. BEXXAR therapy provided substantial evidence of clinical benefit in rituximab-refractory patients and clinical utility in chemotherapy-refractory, low-grade and follicular NHL, with or without transformation. The Company's MELACINE ? melanoma vaccine is available for sale in Canada. MELACINE vaccine consists of lysed (broken) cells from two human melanoma cell lines combined with Corixa's proprietary DETOX? adjuvant. |
|
| Market / Customers |
According to the American Cancer Society, cancer is the second leading cause of death in the U.S. with 13 million new cancer cases have been diagnosed since 1990. Most cancer patients undergo chemotherapy, radiation therapy and surgery, yet most patients are likely to relapse with malignant disease within 10 years following such therapies. Corixa believes that its vaccines and therapeutic antibodies will be most efficacious in those patients who have undergone prior therapy to reduce tumor burden. The Company has one product on the market in Canada. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa technology with the goal of making its potential products available to patients around the world.
|
|
| Competitors / Substitutes / Alternatives |
One potential source of competition for the Company is IDEC Pharmaceuticals, Inc.'s product, Zevalin, which received FDA (Food and Drug Administration) approval for commercial sale in the United States in February 2002. Zevalin has received approval for the treatment of NHL, which is the same approval being sought by the Company for BEXXAR. Other competitors include Biogen Idec, Chiron Corp and Genentech Inc.
|
|
| Strategy |
The Company's primary therapeutic approaches include antibody-based therapeutics, therapeutic vaccines for cancer and infectious disease, agonists and antagonists of innate immune responses and adjuvants designed to increase the effectiveness of its and its partner's vaccines.
|
|
| Funding |
| Corixa announced exercise of initial purchaser's option for additional $15 million. This brings gross proceeds from two recent financing transactions to a total of $130 million. |
|
| Status |
| Together with its partners, Corixa is conducting late-stage clinical trials for several product candidates targeting a range of cancers, infectious diseases and autoimmune diseases. Corixa Corp and GlaxoSmithKline Biologicals (GSK Bio), a developer of vaccines and biologicals, announced that the FDA is allowing the initiation of a Phase I clinical study to evaluate the safety and immunogenicity of a novel, proprietary prophylactic vaccine designed to induce protection against tuberculosis (TB). The trial will be conducted in the United States under the Investigational New Drug Application (IND), currently held by Corixa and will be the first study of this TB vaccine to be conducted in human volunteers. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
